Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on April 12, 2012, Research Triangle Institute, Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the following basic classes of controlled substances:
Drug | Schedule |
---|---|
1-(1-Phenylcyclohexyl)pyrrolidine (7458) | I |
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) | I |
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473) | I |
1-Butyl-3-(1-naphthoyl)indole (7173) | I |
1-Pentyl-3-(1-naphthoyl)indole (7118) | I |
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)Indole (7200) | I |
1-Methyl-4-phenyl-4-propionoxypiperidine (9661) | I |
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (9663) | I |
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (7297) | I |
5-(1,1-Dimethylloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (7298) | I |
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) | I |
2,5-Dimethoxy-4-ethylamphetamine (7399) | I |
2,5-Dimethoxyamphetamine (7396) | I |
3,4,5-Trimethoxyamphetamine (7390) | I |
3,4-Methylenedioxyamphetamine (7400) | I |
3,4-Methylenedioxymethamphetamine (7405) | I |
3,4-Methylenedioxy-N-ethylamphetamine (7404) | I |
3-Methylfentanyl (9813) | I |
3-Methylthiofentanyl (9833) | I |
4-Bromo-2,5-dimethoxyamphetamine (7391) | I |
4-Bromo-2,5-dimethoxyphenethylamine (7392) | I |
4-Methyl-2,5-dimethoxyamphetamine (7395) | I |
4-Methylaminorex (cis isomer) (1590) | I |
4-Methoxyamphetamine (7411) | I |
5-Methoxy-3,4-methylenedioxyamphetamine (7401) | I |
5-Methoxy-N,N-diisopropyltryptamine (7439) | I |
Acetorphine (9319) | I |
Acetyl-alpha-methylfentanyl (9815) | I |
Acetyldihydrocodeine (9051) | I |
Acetylmethadol (9601) | I |
Allylprodine (9602) | I |
Alphacetylmethadol except levo-alphacetylmethadol (9603) | I |
Alpha-ethyltryptamine (7249) | I |
Alphameprodine (9604) | I |
Alphamethadol (9605) | I |
Alpha-methylfentanyl (9814) | I |
Alpha-methylthiofentanyl (9832) | I |
Alpha-methyltryptamine (7432) | I |
Aminorex (1585) | I |
Benzethidine (9606) | I |
Benzylmorphine (9052) | I |
Betacetylmethadol (9607) | I |
Beta-hydroxy-3-methylfentanyl (9831) | I |
Beta-hydroxyfentanyl (9830) | I |
Betameprodine (9608) | I |
Betamethadol (9609) | I |
Betaprodine (9611) | I |
Bufotenine (7433) | I |
Cathinone (1235) | I |
Clonitazene (9612) | I |
Codeine methylbromide (9070) | I |
Codeine-N-Oxide (9053) | I |
Cyprenorphine (9054) | I |
Desomorphine (9055) | I |
Dextromoramide (9613) | I |
Diampromide (9615) | I |
Diethylthiambutene (9616) | I |
Diethyltryptamine (7434) | I |
Difenoxin (9168) | I |
Dihydromorphine (9145) | I |
Dimenoxadol (9617) | I |
Dimepheptanol (9618) | I |
Dimethylthiambutene (9619) | I |
Dimethyltryptamine (7435) | I |
Dioxaphetyl butyrate (9621) | I |
Dipipanone (9622) | I |
Drotebanol (9335) | I |
Ethylmethylthiambutene (9623) | I |
Etonitazene (9624) | I |
Etorphine except HCl (9056) | I |
Etoxeridine (9625) | I |
Fenethylline (1503) | I |
Furethidine (9626) | I |
Gamma Hydroxybutyric Acid (2010) | I |
Heroin (9200) | I |
Hydromorphinol (9301) | I |
Hydroxypethidine (9627) | I |
Ibogaine (7260) | I |
Ketobemidone (9628) | I |
Levomoramide (9629) | I |
Levophenacylmorphan (9631) | I |
Lysergic acid diethylamide (7315) | I |
Marihuana (7360) | I |
Mecloqualone (2572) | I |
Mescaline (7381) | I |
Methaqualone (2565) | I |
Methcathinone (1237) | I |
Methyldesorphine (9302) | I |
Methyldihydromorphine (9304) | I |
Morpheridine (9632) | I |
Morphine methylbromide (9305) | I |
Morphine methylsulfonate (9306) | I |
Morphine-N-Oxide (9307) | I |
Myrophine (9308) | I |
N,N-Dimethylamphetamine (1480) | I |
N-Benzylpiperazine (7493) | I |
N-Ethyl-3-piperidyl benzilate (7482) | I |
N-Ethylamphetamine (1475) | I |
N-Ethyl-1-phenylcyclohexylamine (7455) | I |
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) | I |
Nicocodeine (9309) | I |
Nicomorphine (9312) | I |
N-Methyl-3-piperidyl benzilate (7484) | I |
Noracymethadol (9633) | I |
Norlevorphanol (9634) | I |
Normethadone (9635) | I |
Normorphine (9313) | I |
Norpipanone (9636) | I |
Para-Fluorofentanyl (9812) | I |
Parahexyl (7374) | I |
Peyote (7415) | I |
Phenadoxone (9637) | I |
Phenampromide (9638) | I |
Phenomorphan (9647) | I |
Phenoperidine (9641) | I |
Pholcodine (9314) | I |
Piritramide (9642) | I |
Proheptazine (9643) | I |
Properidine (9644) | I |
Propiram (9649) | I |
Psilocybin (7437) | I |
Psilocyn (7438) | I |
Racemoramide (9645) | I |
Tetrahydrocannabinols (7370) | I |
Thebacon (9315) | I |
Thiofentanyl (9835) | I |
Tilidine (9750) | I |
Trimeperidine (9646) | I |
1-Phenylcyclohexylamine (7460) | II |
1-Piperidinocyclohexanecarbonitrile (8603) | II |
4-Anilino-N-phenethyl-4-piperidine (8333) | II |
Alfentanil (9737) | II |
Alphaprodine (9010) | II |
Amobarbital (2125) | II |
Amphetamine (1100) | II |
Anileridine (9020) | II |
Bezitramide (9800) | II |
Carfentanil (9743) | II |
Coca Leaves (9040) | II |
Cocaine (9041) | II |
Codeine (9050) | II |
Dextropropoxyphene, bulk (non-dosage forms) (9273) | II |
Dihydrocodeine (9120) | II |
Dihydroetorphine (9334) | II |
Diphenoxylate (9170) | II |
Ecgonine (9180) | II |
Ethylmorphine (9190) | II |
Etorphine HCl (9059) | II |
Fentanyl (9801) | II |
Glutethimide (2550) | II |
Hydrocodone (9193) | II |
Hydromorphone (9150) | II |
Isomethadone (9226) | II |
Levo-alphacetylmethadol (9648) | II |
Levomethorphan (9210) | II |
Levorphanol (9220) | II |
Lisdexamfetamine (1205) | II |
Meperidine (9230) | II |
Meperidine intermediate-A (9232) | II |
Meperidine intermediate-B (9233) | II |
Meperidine intermediate-C (9234) | II |
Metazocine (9240) | II |
Methadone (9250) | II |
Methadone intermediate (9254) | II |
Methamphetamine (1105) | II |
Methylphenidate (1724) | II |
Metopon (9260) | II |
Moramide intermediate (9802) | II |
Morphine (9300) | II |
Nabilone (7379) | II |
Opium, raw (9600) | II |
Opium extracts (9610) | II |
Opium fluid extract (9620) | II |
Opium tincture (9630) | II |
Opium poppy/Poppy Straw (9650) | II |
Poppy Straw Concentrate (9670) | II |
Opium, granulated (9640) | II |
Oxycodone (9143) | II |
Oxymorphone (9652) | II |
Pentobarbital (2270) | II |
Phenazocine (9715) | II |
Phencyclidine (7471) | II |
Phenmetrazine (1631) | II |
Phenylacetone (8501) | II |
Piminodine (9730) | II |
Powdered opium (9639) | II |
Racemethorphan (9732) | II |
Racemorphan (9733) | II |
Remifentanil (9739) | II |
Secobarbital (2315) | II |
Sufentanil (9740) | II |
Tapentadol (9780) | II |
Thebaine (9333) | II |
The company plans to import small quantities of the listed controlled substances for the National Institute on Drug Abuse (NIDA) for research activities.
Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417 (2007).
In regard to the non-narcotic raw material, any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.
Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 9, 2012.
This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745-46, all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: May 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 2012-13920 Filed 6-7-12; 8:45 am]
BILLING CODE 4410-09-P